Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.
about
ICOS Co-Stimulation: Friend or Foe?Advances in Cancer Immunotherapy in Solid TumorsB cells and the humoral response in melanoma: The overlooked players of the tumor microenvironmentPD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations.Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.Increased Pretransplant Frequency of CD28+ CD4+ TEM Predicts Belatacept-Resistant Rejection in Human Renal Transplant Recipients.Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance.Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses.Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations.Developing Cures: Targeting Ontogenesis in Cancer.Adoptively transferred Vγ9Vδ2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model."The Impact of Mycobacterium tuberculosis Immune Evasion on Protective Immunity: Implications for TB Vaccine Design" - Meeting report.In situ and in silico kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network.Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes.CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis.PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells.A distinct innate lymphoid cell population regulates tumor-associated T cells.STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC.Glycogen Synthase Kinase 3 Inactivation Compensates for the Lack of CD28 in the Priming of CD8+ Cytotoxic T-Cells: Implications for anti-PD-1 Immunotherapy.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Immune checkpoint inhibitors in advanced non-small cell lung cancer.The immune checkpoint molecule VISTA regulates allergen-specific Th2-mediated immune responses.The diverse functions of the PD1 inhibitory pathway.Immunotherapies for malignant glioma.Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.Inhibitors of the PD-1 Pathway in Tumor Therapy.Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report.GATA3, HDAC6, and BCL6 Regulate FOXP3+ Treg Plasticity and Determine Treg Conversion into Either Novel Antigen-Presenting Cell-Like Treg or Th1-Treg.Inducible Costimulator Contributes to Methicillin-Resistant Staphylococcus aureus Pneumonia.Tim-3, Lag-3, and TIGIT.Early B cell changes predict autoimmunity following combination immune checkpoint blockade.Dynamics of tissue-specific CD8+ T cell responses during West Nile virus infection.
P2860
Q28072305-1A52CDE2-CFE2-407C-94F0-40F720D38FBAQ28080113-E6A81027-9E4A-43D3-AF0D-4D3AB740C051Q33632113-1DFDFD2A-1F8D-463F-BE84-7D2B38872F16Q34550012-0CF1C5D8-7846-4B75-97A8-04B9BD347B42Q37486606-8712CAA5-2715-4A31-BEA7-EAE6EB2F1001Q38718016-7293E5A7-B7CC-46A0-AF50-0040747356F8Q38779877-DAB5A302-E66D-4E1A-A107-4218BB6EC1C6Q38787359-A36A7862-316E-4CFE-B8E8-DD0B7CABEDC5Q38999322-0F38C8E1-DCF8-4A06-A90D-59AA59AF2480Q39085984-A0410D01-7ABD-46F8-8D80-13E634745DA0Q39245827-4D79275F-2115-4796-A4BB-F1B0BFE211F2Q39262779-4CB2BB38-B631-422E-A02F-F18866F68620Q39313794-4B5B9766-7B26-43A7-86BF-AB932837826AQ39363726-41497713-F6C7-4A77-8BC7-6247BC97A7AAQ39441380-9747BBC7-1633-4FCF-B17E-CC48C2EF7E85Q40146526-509E2D08-8487-4226-81DA-054A40B9F2C3Q40213126-605734B2-89BE-48D2-A58E-5B9FADA4A67CQ40304447-7F695FD6-698C-4DF5-A028-A2BB0591FE4EQ41173680-A1BAEE65-B21E-4402-9CA7-8AAE67C09983Q41703479-63700B49-5D8B-469B-8BE0-FA8D5C2D47E1Q42017141-89265AFA-EEED-4F7D-B3EB-32A2641356FBQ42256164-359BEA54-C243-49C7-B54B-F0D7C1BFCF88Q46758818-A7908F01-E5C6-41D8-BCB8-AA6867EAD300Q47122059-C0F74164-085E-4E05-9915-938B1B51A2DDQ47223979-A9642B6C-F6BD-4709-A9E9-BE8C17951921Q47325431-E66F0AD1-2359-4F02-B3B2-98B424D7EF59Q47563451-D1922B60-9917-4CF5-9C04-D10246FA4846Q47673859-4E2AA28D-D3BD-48DA-B595-95D3A7A8A2ACQ47678849-CCB2D388-209B-4FDF-913A-0D3F30EACB7EQ47915209-8359C99A-4BB4-4AA2-96B3-CD53B707CAC4Q47986213-2BD5DCEB-ED24-4EA9-91EA-C17D8F67DBE4Q48201416-04B7A631-7271-4F0C-8430-EB77A4EAC82AQ48256829-E5065A3A-2E43-4CAD-93DD-B3D81E7780B2Q48293633-B2C201A8-5192-48B5-9DE8-D046F9108800Q49383236-85E4D1FF-2A3F-48D7-8423-2B13DC638A30Q49474705-185A157D-028C-4AB0-B06E-D0CFE2D0FBC4Q49604318-B5AAE292-C5C5-489C-B3F4-6370D75176CFQ50125564-8376A5E1-A3CD-493E-9658-3B256ED6CEA0Q50140526-301D1ABB-D016-4421-8BE1-B39DAA3ECC30Q50532061-84CA4C74-8477-4322-B902-7950F59B1041
P2860
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.
@en
type
label
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.
@en
prefLabel
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.
@en
P2093
P2860
P1433
P1476
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.
@en
P2093
Arlene H Sharpe
Frank A Schildberg
Gordon J Freeman
Sarah R Klein
P2860
P304
P356
10.1016/J.IMMUNI.2016.05.002
P407
P577
2016-05-01T00:00:00Z